CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
Capital Com Australia Pty Ltd Australia (受监管于 ASIC) Capital Com UK Limited 受监管于 Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (受监管于 CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (受监管于 NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (受监管于 FSA) Capital Com Online Investments Ltd (受监管于 SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
您也可以联系我们： 致电 +44 2030978888 support@capital.com

交易 Kaleido Biosciences, Inc. - KLDO CFD

0.38
0%
  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 0.05
多头隔夜费

Long position overnight fee

Margin. Your investment $1,000.00
隔夜费用 -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
-0.024068%
空头隔夜费

Short position overnight fee

Margin. Your investment $1,000.00
隔夜费用 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
0.001846%
隔夜费时间 21:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

关键数据
前收盘价* 0.39
开盘价* 0.4
1 年变化* 2.56%
日范围* 0.38 - 0.45
52 周范围 0.00-1.92
平均交易量（10 天） 26.79K
平均交易量（3 个月) 306.37K
市值 8,520.00
市盈率 -100.00K
流通股 42.62M
收入 1.10M
EPS -2.16
股息（收益率 %） N/A
贝塔 0.47
下一个财报发布日期 Mar 23, 2023

所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平倉 Change Change (%) 開倉 High Low
Apr 14, 2022 0.38 0.00 0.00% 0.38 0.38 0.38
Apr 13, 2022 0.39 0.00 0.00% 0.39 0.47 0.38
Apr 8, 2022 0.40 -0.24 -37.50% 0.64 0.64 0.38
Apr 7, 2022 1.46 -0.01 -0.68% 1.47 1.55 1.42
Apr 6, 2022 1.46 -0.02 -1.35% 1.48 1.48 1.42
Apr 5, 2022 1.50 -0.09 -5.66% 1.59 1.62 1.48
Apr 4, 2022 1.59 -0.14 -8.09% 1.73 1.73 1.54
Apr 1, 2022 1.68 0.06 3.70% 1.62 1.70 1.58
Mar 31, 2022 1.60 -0.08 -4.76% 1.68 1.72 1.55
Mar 30, 2022 1.69 -0.14 -7.65% 1.83 1.83 1.69
Mar 29, 2022 1.70 0.02 1.19% 1.68 1.77 1.60
Mar 28, 2022 1.60 -0.13 -7.51% 1.73 1.73 1.50
Mar 25, 2022 1.64 -0.10 -5.75% 1.74 1.74 1.63
Mar 24, 2022 1.74 0.00 0.00% 1.74 1.76 1.68
Mar 23, 2022 1.74 0.01 0.58% 1.73 1.81 1.73
Mar 22, 2022 1.75 0.10 6.06% 1.65 1.75 1.65
Mar 21, 2022 1.63 -0.05 -2.98% 1.68 1.68 1.55
Mar 18, 2022 1.67 0.14 9.15% 1.53 1.71 1.53
Mar 17, 2022 1.56 0.14 9.86% 1.42 1.57 1.42
Mar 16, 2022 1.42 0.04 2.90% 1.38 1.42 1.31

Kaleido Biosciences, Inc. Events

時間（協調世界時） (UTC) 國家 事件
No events scheduled
查看所有活動
  • 年度
  • 每季度
2021 2020 2019 2018 2017
总收入 1.104 0.975 0 0 0
总营业费用 88.771 79.849 87.24 60.683 27.03
销售/一般/行政费用，总计 20.968 23.882 22.428 18.621 6.038
研究与开发 67.803 55.967 64.232 42.062 20.992
营业收入 -87.667 -78.874 -87.24 -60.683 -27.03
利息收入（费用），非经营净值 -2.766 -2.553 0.968 -0.805 -0.512
其他，净值 0.145 -0.193 -0.059 -0.256 -0.017
税前净收入 -90.288 -81.62 -86.331 -61.744 -27.559
税后净收入 -90.288 -81.62 -86.331 -61.744 -27.559
未计算非常项目前的净收益 -90.288 -81.62 -86.331 -61.744 -27.559
净收入 -90.288 -81.62 -86.331 -61.744 -27.559
普通股股东可获收益 (不含非经常性项目) -90.288 -81.62 -86.331 -61.744 -27.559
普通股股东可获收益 (含非經常性項目) -90.288 -81.62 -86.331 -61.744 -27.559
摊薄净收入 -90.288 -81.62 -86.331 -61.744 -27.559
摊薄后加权平均股 41.86 33.4502 25.7033 29.3948 29.3948
扣除特别项目的每股摊薄盈利 -2.1569 -2.44004 -3.35876 -2.10051 -0.93755
Dividends per Share - Common Stock Primary Issue 0 0
每股正常摊薄盈利 -2.1569 -2.44004 -3.33619 -2.10051 -0.93755
异常费用（收入） 0 0.58
收入 1.104 0.975
Dec 2021 Sep 2021 Jun 2021 Mar 2021 Dec 2020
总收入 0.492 0.104 0.211 0.297 0.243
收入 0.492 0.104 0.211 0.297 0.243
总营业费用 20.191 22.517 23.418 22.645 19.543
销售/一般/行政费用，总计 4.617 5.106 5.785 5.46 5.205
研究与开发 15.574 17.411 17.633 17.185 14.338
异常费用（收入） 0
营业收入 -19.699 -22.413 -23.207 -22.348 -19.3
利息收入（费用），非经营净值 -0.705 -0.692 -0.681 -0.688 -0.713
其他，净值 0.132 0.02 -0.001 -0.006 -0.003
税前净收入 -20.272 -23.085 -23.889 -23.042 -20.016
税后净收入 -20.272 -23.085 -23.889 -23.042 -20.016
未计算非常项目前的净收益 -20.272 -23.085 -23.889 -23.042 -20.016
净收入 -20.272 -23.085 -23.889 -23.042 -20.016
普通股股东可获收益 (不含非经常性项目) -20.272 -23.085 -23.889 -23.042 -20.016
普通股股东可获收益 (含非經常性項目) -20.272 -23.085 -23.889 -23.042 -20.016
摊薄净收入 -20.272 -23.085 -23.889 -23.042 -20.016
摊薄后加权平均股 42.5995 42.5776 42.5386 39.6926 35.9841
扣除特别项目的每股摊薄盈利 -0.47587 -0.54219 -0.56158 -0.58051 -0.55625
每股正常摊薄盈利 -0.47587 -0.54219 -0.56158 -0.58051 -0.55625
Dividends per Share - Common Stock Primary Issue 0 0 0
  • 年度
  • 每季度
2021 2020 2019 2018 2017
流动资产总额 42.311 48.721 73.279 76.243 28.551
现金和短期投资 38.474 46.222 71.241 76.086 28.456
现金等价物 38.474 46.222 71.241 76.086 28.456
应收账款总额，净额 0.005 0.045
Prepaid Expenses 3.583 2.499 2.038 0.152 0.05
Total Assets 50.137 59.344 82.306 85.325 30.747
Property/Plant/Equipment, Total - Net 5.665 8.462 6.742 4.693 1.975
Property/Plant/Equipment, Total - Gross 11.136 11.955 9.281 5.914 2.406
Accumulated Depreciation, Total -5.471 -3.493 -2.539 -1.221 -0.431
Other Long Term Assets, Total 2.161 2.161 2.285 4.389 0.221
Total Current Liabilities 29.682 16.659 10.377 11.301 3.854
Accounts Payable 5.67 5.389 2.016 3.442 0.864
Accrued Expenses 6.686 7.356 7.086 7.406 2.615
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 16.144 2.634 0.068 0.091 0.104
Other Current Liabilities, Total 1.182 1.28 1.207 0.362 0.271
Total Liabilities 39.53 38.848 33.423 28.343 21.932
Total Long Term Debt 5.55 18.375 20.391 14.831 14.81
Long Term Debt 5.55 18.375 20.391 14.831 14.81
Other Liabilities, Total 4.298 3.814 2.655 2.211 3.268
Total Equity 10.607 20.496 48.883 56.982 8.815
Preferred Stock - Non Redeemable, Net 153.226 52.494
Common Stock 0.043 0.036 0.03 0.006 0.005
Additional Paid-In Capital 375.031 294.639 241.412 9.978 0.8
Retained Earnings (Accumulated Deficit) -364.467 -274.179 -192.559 -106.228 -44.484
Total Liabilities & Shareholders’ Equity 50.137 59.344 82.306 85.325 30.747
Total Common Shares Outstanding 42.596 36.0228 30.1278 29.3948 29.3948
Redeemable Preferred Stock 0 0
Other Current Assets, Total 0.254
Dec 2021 Sep 2021 Jun 2021 Mar 2021 Dec 2020
流动资产总额 42.311 58.304 74.603 95.032 48.721
现金和短期投资 38.474 55.657 71.979 92.362 46.222
现金等价物 38.474 55.657 71.979 92.362 46.222
Prepaid Expenses 3.583 2.647 2.624 2.67 2.499
Total Assets 50.137 67.804 84.29 105.026 59.344
Property/Plant/Equipment, Total - Net 5.665 7.339 7.526 7.833 8.462
Property/Plant/Equipment, Total - Gross 11.136 12.482 12.165 11.889 11.955
Accumulated Depreciation, Total -5.471 -5.143 -4.639 -4.056 -3.493
Other Long Term Assets, Total 2.161 2.161 2.161 2.161 2.161
Total Current Liabilities 29.682 19.261 12.269 12.873 16.659
Accounts Payable 5.67 3.559 2.695 2.412 5.389
Accrued Expenses 6.686 8.681 5.014 4.403 7.356
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 16.144 6.384 3.667 4.759 2.634
Other Current Liabilities, Total 1.182 0.637 0.893 1.299 1.28
Total Liabilities 39.53 38.604 34.024 33.252 38.848
Total Long Term Debt 5.55 15.132 17.677 16.433 18.375
Long Term Debt 5.55 15.132 17.677 16.433 18.375
Other Liabilities, Total 4.298 4.211 4.078 3.946 3.814
Total Equity 10.607 29.2 50.266 71.774 20.496
Common Stock 0.043 0.043 0.043 0.042 0.036
Additional Paid-In Capital 375.031 373.352 371.333 368.953 294.639
Retained Earnings (Accumulated Deficit) -364.467 -344.195 -321.11 -297.221 -274.179
Total Liabilities & Shareholders’ Equity 50.137 67.804 84.29 105.026 59.344
Total Common Shares Outstanding 42.596 42.5801 42.5714 42.4832 36.0228
Redeemable Preferred Stock 0 0
Other Current Assets, Total 0.254
  • 年度
  • 每季度
2021 2020 2019 2018 2017
净收入/起跑线 -90.288 -81.62 -86.331 -61.744 -27.559
经营活动产生的现金 -77.094 -61.518 -75.796 -46.316 -22.495
经营活动产生的现金 2.358 1.823 1.318 0.792 0.316
非现金物品 11.099 13.728 10.433 8.14 0.738
已付现金利息 2.133 1.925 0.881 0.943 0.343
营运资金的变化 -0.263 4.551 -1.216 6.496 4.01
投资活动产生的现金 -0.691 -4.024 -3.586 -3.002 -1.406
资本支出 -1.129 -4.024 -3.586 -3.002 -1.406
融资活动产生的现金 70.037 40.399 74.642 98.907 49.736
融资现金流项目 -0.359 -0.079 -1.158 -1.84 0
股票的发行（报废），净额 70.396 40.546 68.391 100.852 39.86
债务的发行（退还），净额 0 -0.068 7.409 -0.105 9.876
现金净变化 -7.748 -25.143 -4.74 49.589 25.835
其他投资现金流量项目，总计 0.438
Dec 2021 Sep 2021 Jun 2021 Mar 2021 Dec 2020
Net income/Starting Line -90.288 -70.016 -46.931 -23.042 -81.62
Cash From Operating Activities -77.094 -59.934 -44.057 -23.974 -61.518
Cash From Operating Activities 2.358 1.754 1.16 0.577 1.823
Non-Cash Items 11.099 9.331 7.146 4.603 13.728
Cash Interest Paid 2.133 1.601 1.064 0.526 1.925
Changes in Working Capital -0.263 -1.003 -5.432 -6.112 4.551
Cash From Investing Activities -0.691 -0.693 -0.262 -0.03 -4.024
Capital Expenditures -1.129 -0.693 -0.262 -0.03 -4.024
Cash From Financing Activities 70.037 70.062 70.076 70.144 40.399
Financing Cash Flow Items -0.359 -0.329 -0.31 -0.186 -0.079
Issuance (Retirement) of Stock, Net 70.396 70.391 70.386 70.33 40.546
Issuance (Retirement) of Debt, Net 0 0 0 -0.068
Net Change in Cash -7.748 9.435 25.757 46.14 -25.143
Other Investing Cash Flow Items, Total 0.438
投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
Menichella (Daniel L.) Individual Investor 0.2996 127700 107700 2022-03-31 MED
Duke (William E. Jr.) Individual Investor 0.1598 68115 68115 2022-03-31 LOW
Korn (Jerald) Individual Investor 0.1215 51803 51803 2022-03-31
Melas-Kyriazi (Theo) Individual Investor 0.0782 33333 0 2022-03-31 LOW
Quinn (Anthony G) Individual Investor 0.0741 31603 0 2022-03-31 LOW
Northern Trust Global Investments Investment Advisor 0.0334 14235 14235 2022-12-31 LOW
DWS Investments UK Limited Investment Advisor 0.0244 10387 0 2023-02-28 MED
Amalgamated Financial Corp. Investment Advisor 0.0077 3266 3266 2022-03-31
Mackenzie Financial Corporation Investment Advisor/Hedge Fund 0.0027 1139 -148 2022-09-30 LOW
Westfield Capital Management Company, L.P. Investment Advisor/Hedge Fund 0.002 854 0 2021-09-30 LOW
Carroll Financial Associates, Inc. Investment Advisor 0.0008 339 0 2021-12-31

为什么选择 Capital.com？让我们的数字来说话。

Capital.com Group

500K+

交易者

92K+

每月活跃客户

$53M+

每月投资额

$30M+

每月提取金额

交易計算器

如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

貿易佣金
0
  • 1:1
杠杆
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投資
交易規模（槓桿 x 投資）：
開倉

平倉

做空 做多
過去的表現並不是未來結果的可靠指標
盈利/失利

Kaleido Biosciences, Inc. Company profile

关于 Kaleido Biosciences Inc.

Kaleido Biosciences, Inc.是一家临床阶段的医疗保健公司，致力于利用微生物组器官的潜力来治疗疾病和改善人类健康。 其微生物组代谢疗法（MMTs）旨在推动微生物组现有微生物的功能和分布，以减少或增加对微生物组群中某些细菌的代谢产物的产生。 公司还在推进一个广泛的候选微生物组的管道，有可能解决各种疾病和病人需求得不到满足的状况。 公司利用其发现和开发平台研究微生物组样本中的MMTs，以快速推进MMT候选药物在健康人和病人中的临床研究。 公司的KB195是用于治疗尿素循环障碍患者的主要MMT候选药物。 公司正在根据一项新药研究申请（IND）进行II期临床试验。

Industry: Biotechnology & Medical Research (NEC)

18 Crosby Dr
BEDFORD
MASSACHUSETTS 01730-1402
US

收入报表

  • Annual
  • Quarterly

人们也观看

Oil - Crude

70.48 Price
+0.770% 1D Chg, %
多头隔夜费 -0.0170%
空头隔夜费 -0.0050%
隔夜费时间 21:00 (UTC)
价差 0.03

US100

12,667.90 Price
+0.820% 1D Chg, %
多头隔夜费 -0.0241%
空头隔夜费 0.0018%
隔夜费时间 21:00 (UTC)
价差 1.8

Gold

1,977.80 Price
+0.390% 1D Chg, %
多头隔夜费 -0.0086%
空头隔夜费 0.0004%
隔夜费时间 21:00 (UTC)
价差 0.30

XRP/USD

0.43 Price
+1.290% 1D Chg, %
多头隔夜费 -0.0753%
空头隔夜费 0.0069%
隔夜费时间 21:00 (UTC)
价差 0.00344

还在找一位您可以信任的经纪商吗？

加入成为全球500,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易